Mirror, mirror on the wall, which is the fairest meta-analysis of all?

Critical Care Medicine

Volumn 35, Issue 12, 2007, Pages 2852-2854

  Werdan, Karl ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INSULIN;

ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 36448954721     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000297164.40980.F0     Document Type: Editorial

References (16)

1. Alejandria MM, Lansang MA, Dans LF, et al: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002; CD001090
2. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
3. Pildal J, Gotzsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: A systematic review. Clin Infect Dis 2004; 39:38-46
4. Norrby-Teglund A, Haque KN, Hammarström L: Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: A review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006; 260:509-516
5. Laupland K, Kirkpatrick AW, Delaney A: Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit Care Med 2007; 35:2686-2692
6. Kreymann KG, de Heer G, Nierhaus A, et al: Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35:2677-2685
7. Werdan K, Pilz G, Bujdoso O, et al: Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 2007; 35:2693-2701
8. Werdan K, Pilz G, Mueller-Werdan U, et al: Immune globulin G treatment of post cardiac surgery patients with score-identified severe SIRS - The ESSICS study. Crit Care Med 2008; 36:In Press
9. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755
10. Trautmann M, Held TK, Susa M, et al: Bacterial lipopolysaccharide (LPS)specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998; 111:81-90
11. Rieben R, Roos A, Muizert Y, et al: Immunoglobulin M enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999; 93:942-951
12. Hoffmann JN, Fertmann JM, Vollmar B, et al: Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 2007 [Online ahead of print]
13. Andersson JP, Andersson UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71:372-376
14. Mohr M, Englisch L, Roth A, et al: Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997; 23:1144-1149
15. Schedel I, Dreickhausen U, Nentwig B, et al: Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-1113
16. Reinhart K, Brunkhorst FM, Bone H-G, et al: Diagnosis and treatment of sepsis: S-2 guidelines of DSG and DIVI. Intensivmed 2006; 43:369-384; 464-475